Www.OncologyEducation.ca Efficacy of BSI-201, a PARP-Inhibitor in combination with Gemcitabine/Carboplatin in Triple Negative Breast Cancer: Randomized.

Slides:

Advertisements

Similar presentations

Miles DW et al. SABCS 2009;Abstract 41.

Advertisements

Miles D et al. Proc SABCS 2012;Abstract P

San Antonio Breast Cancer Symposia Authors: Dr. Sunil Verma Date posted: January 6 th, 2008.

SABCS 2011 BOLERO-2 Updated Results

Triple negative breast cancer

Triple-Negative Breast Cancer

A trial for women with –‘Triple negative’ breast cancer (TNBC) –Localised to breast +/- lymph nodes –Recommended standard treatment involves NEPTUNE Taxane.

Randomized Trial of p53 Targeted Adjuvant Therapy for Patients (pts) With Organ-Confined Node-Negative Urothelial Bladder Cancer.

Can We Define Tumors That Will Respond to PARP Inhibitors? A Phase II Correlative Study of Olaparib in Advanced Serous Ovarian Cancer and Triple-Negative.

What are clinical trials? Phases of Clinical Trials Clinical trials of new medicines are done in phases: Phase I Phase II Phase III.

Targeted Therapy: A Giant Step Forward

Unanswered Questions in Primary Treatment of Ovarian Cancer: Controversial Areas Deborah K. Armstrong, M.D. May 29, 2009.

Understanding and Treating Triple-Negative Breast Cancer Elshami M. Elamin, MD Medical Oncologist Central Care Cancer Center Wichita,

A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)

Drug Treatment of Metastatic Breast Cancer

CELLULAR BIOLOGY IN BREAST CANCER JESSE ELLMAN MD SEPT 2010 CLINICAL ASSISTANT PROFESSOR DEPT OB GYN AND WOMENS HEALTH WE MAY BE ENTERING A NEW PHASE.

New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative.

Phase 1b Study of Iniparib (BSI-201) Combined with Irinotecan for Treatment of Metastatic Breast Cancer 1 Cell Cycle Effects of Iniparib plus Gemcitabine.

Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.

ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

A Meta-Analysis of Overall Survival Data from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Patients with Metastatic.

BIG 1-98/IBCSG Henning Mouridsen for the BIG 1-98 Collaborative Group Authors: Sunil Verma Date posted: December 22, 2008.

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin in Triple Negative Metastatic Breast Cancer: Results of a Phase II Study.

ESMO 2011 Breast Cancer Trastuzumab in untreated MBC Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October.

Educational Objectives Metastatic Breast Cancer: Scope of the Problem.

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

O’Shaughnessy J et al. Proc ASCO 2011;Abstract 1007.

WHAT WILL THE KEY ISSUES IN END- POINT ASSESSMENT BE, IN FUTURE OVARIAN CANCER TRIALS INVOLVING NOVEL TARGETED AGENTS? first line treatment maintenance/consolidation.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

ECCO ESMO 2011 GI Cancer Updates TAS102 and BSC vs. Placebo and BSC Reviewer: Dr. Scott Berry Date posted: October 2011.

Results of a Randomized Phase 2 Study of PD , a Cyclin ‐ Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone.

Audeh MW et al. ASCO 2009; Abstract (Clinical Science Symposium)

ESMO 2011 Breast Cancer BOLERO-2 Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October 12, 2011.

ASCO 2009 BEVACIZUMAB IN METASTATIC RENAL CELL CARCINOMA: An Update of the CALGB and AVOREN Trials Reviewed by: Dr. Daniel.

Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) Update Authors: Hecht et al at ASCO GI 2008 Date posted: April

FinXX trial Authors: Sunil Verma Date posted: December 22 nd, 2008.

ESMO 2011 Lung Cancer Vantage 014 Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Cancer. Cancer is a disease of the cell cycle Caused by one or more of the following: Increase in growth signals Loss of inhibitory signals In addition,

Five Year Update of Cardiac Dysfunction in NSABP B-31 A Randomized Trial of AC  Paclitaxel vs. AC  Paclitaxel with Trastuzumab.

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.

Triple-Negative and BRCA-Mutated Metastatic Breast Cancer

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

Presented By Luca Malorni at 2017 ASCO Annual Meeting

The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities.

Metastatic HER2+ Breast Cancer: Resistance

An Introduction to DNA Damage Repair in Cancer: Beyond PARP

BRCA, HRR Deficiency, and PARP Inhibitors

سرطان الثدي Breast Cancer

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

PARP Inhibitors and Cancer: What Do You Need to Know?

Managing gBRCA-Positive Metastatic Breast Cancer

Individualizing Care in Ovarian Cancer

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Advancing Care Across the Spectrum of Pancreatic Cancer

PARP Inhibitors.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.

EVOLUTION OF PARP INHIBITORS IN OVARIAN CANCER

Felix Y. Feng, Johann S. de Bono, Mark A. Rubin, Karen E. Knudsen

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Authors: Sunil Verma Date posted: December 22, 2008

Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.

Presentation transcript:

Efficacy of BSI-201, a PARP-Inhibitor in combination with Gemcitabine/Carboplatin in Triple Negative Breast Cancer: Randomized Phase II trial Presented by Dr. Joyce OShaughnessey Authors: Dr. Sunil Verma Date posted: June 22 nd, 2009

Background Triple Negative (TN) disease represents the next frontier in Breast Cancer TN disease shares key features with Basal-like and BRCA associated cancer –BRCA dysfunction –Susceptibility to DNA damaging agents In the setting of BRCA dysfunction, the cancer cell increasingly relies on PARP for DNA repair process –This may represent an important therapeutic target

R Treatment A: Gemcitabine +Carboplatin Treatment B: Gemcitabine + Carboplatin + BSI-201 (a PARP – inhibitor) Triple Negative MBC

RESULTS Treatment A Treatment B p-value Response Rate (%) 16%48%0.002 PFS/TTP (median, mos) 3.3 m6.9 m< OS (median, mos) 5.7 m9.2 m0.0005

STUDY COMMENTARY This is an important study as it shows that the addition of PARP- inhibitors to chemotherapy improves the outcome for TN MBC This is the first Phase II trial evaluating this class of drugs in MBC There is a planned Phase III trial designed to evaluate BSI-201 in combination with carboplatin+gemcitabine There are some unanswered questions related to this class of drugs: - Do PARP-Inhibitors need DNA damaging stimulus? -Will they be effective in a broader subgroup of patients? TN Non-TN - What are the long-term toxicities associated with these agents? ? Increase risk of tumorogenesis - Oral vs. IV

BOTTOM LINE FOR CANADIAN MEDICAL ONCOLOGISTS Triple Negative Breast Cancer is associated with poor prognosis and represents an aggressive phenotype of breast cancer. Majority of TN disease is associated with basal-like profile. Furthermore, basal-like breast cancer shares a number of features associated with BRCA related cancers TN breast cancer may particularly be sensitive to DNA damaging agents including Cisplatin and PARP inhibitors This study suggests that PARP inhibitors are efficacious for TN MBC While the results from this Phase II trial are impressive, there are still a number of unanswered questions and future trials evaluating PARP- inhibitors will help establish the magnitude of benefit and their role for early stage and advanced TN breast cancer